Associate Professor
Hematology
Dr. Sunita D. Nasta, MD
|
|
Give Review
Sunita Nasta practices Hematology. She attended Baylor College of Medicine. She received awards:"Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Sunita Nasta has written publications. She has 52 publications published with PubMed. The lastest paper is: 'Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.' She is registered with Medicare and accepts Medicare payments.
Publications
- Ibrutinib-induced pneumonitis in patients with chronic lymphocytic Leukemia.
- Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large...
- Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell Acute lymphoblastic leukaemia and lymphoma.
- Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.
- Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a Systematic ...
- High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.
- Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
- A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus p...
- The importance of multidisciplinary healthcare for paraneoplastic pemphigus.
- The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell Lymphoma.
- R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma.
- 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell Lymphoma ...
- Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET.
- Could treatment with R-HCVAD/R-MA as compared to R-CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell Lymphoma?
- Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell Lymphomas.
- Receipt of maintenance therapy is most predictive of survival in older Acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.
- Outcomes of patients with relapsed/refractory diffuse large B-cell Lymphoma with progression of Lymphoma after autologous stem cell transplantation in the rituximab era.
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell Lymphoma.
- Potential prolongation of PFS in mantle cell Lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance.
- Blockade of lymphocyte chemotaxis in visceral Graft-versus-host disease.
- Allogeneic hematopoietic SCT for primary cutaneous T cell Lymphomas.
- Prediction and Early Detection of Response by NMR Spectroscopy and Imaging.
- Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell Lymphoma.
- NMR metabolic and physiological markers of therapeutic response.
- Determinants of the optimal first-line therapy for follicular lymphoma: a decision Analysis.
- A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory Acute myelogenous leukemia.
- A novel regimen of vorinostat with interferon gamma for refractory Sézary Syndrome.
- Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphala...
- Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's Lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
- Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal Cancer.
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event Analyses of the multicenter phase 2 PINNACLE study.
- Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive Disease.
- Prognostic value of FDG-PET scan imaging in Lymphoma patients undergoing autologous stem cell transplantation.
- Intensive Graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
- Treatment of PTLD with rituximab or chemotherapy.
- Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular Lymphoma.
- Presence of Erdheim-Chester Disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases.
- Myocarditis during lenalidomide therapy.
- Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's Lymphoma: resul...
- Clinical and in vitro resistance to bexarotene in adult T-cell Leukemia: loss of RXR-alpha receptor.
- Successful treatment of angioimmunoblastic T-cell Lymphoma with the retinoid X receptor agonist, bexarotene.
- Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive Disease after stem cell transplantation.
- A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.
- CD8+ Lymphoma in a patient with human immunodeficiency virus.
- Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.
- Primary Lymphomas of the cervix and uterus: the University of Pennsylvania''s experience and a review of the literature.
- Use of iodine 131I-toSitumomab radioimmunotherapy in a patient with Waldenstrom''s macroglobulinemia.
- Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder.
- Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.
- Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid Analog bexarotene.
- Regression of a plasmablastic Lymphoma in a patient with HIV on highly active antiretroviral therapy.
Schools
Virginia Commonwealth University School Of Medicine
Baylor College Of Med
MD Anderson Cancer Ct
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas MD Anderson Cancer Center -
Baylor College of Medicine -
Virginia Commonwealth University School of Medicine -
Stanford University
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1336180108 | |
| NPPES Provider LastName | NASTA | |
| NPPES Provider FirstName | SUNITA | |
| NPPES Provider ZIPCode | 191045127 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 276.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 4.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336180108 |
| Last Name Of The Provider | NASTA |
| First Name Of The Provider | SUNITA |
| View All |
Similar Doctors
|
|
Dr. Tahamtan Ahmadi, MD |
|
|
Dr. Eugene J. Choi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert D. Leone, MD |
|
|
Dr. Joseph N. Tropea, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan C. Weil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael V. Seiden, MD |
|
|
Dr. Angela Jain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas R. Klumpp, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark S. Morginstin, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Capizzi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Millenson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Edith P. Mitchell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dan T. Vogl, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Y. Chiang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meghan S. Karuturi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sramila Aithal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dhaval T. Mehta, MD |
|
Dr. Aruna Padmanabhan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jing-Mei Hsu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Stadtmauer, MD
This Doctor is OpenDoctor Recommended.
|